Roger Klein Profile (Claude Opus 4.7)

 

---

Roger D. Klein at AHRQ: A Profile in Ideological Transition [Claude Opus 4.7]

Bruce, this is a useful moment to sit down with the Klein file, because the May 22 Precision Medicine Online piece is really a snapshot from the middle of a much longer arc. The Klein who tells Alex Krist's old colleagues "the Task Force will meet this summer" is the same person who spent fifteen years on the Federalist Society circuit arguing that federal evidence-review machinery was overbearing, captured, and slow. Putting him in charge of USPSTF is not an accident of personnel; it's a thesis being tested.

The Academic and Professional Backbone

Klein's CV is genuinely substantial within a narrow but real niche. He took his MD at Case Western Reserve, did residency and fellowships at Yale, picked up a Molecular Genetic Pathology fellowship at Mayo, and then circled back to Yale Law School, where he was an articles editor at the Yale Journal on Regulation and an Olin Fellow in Law, Economics, and Public Policy — the Olin Fellowship being a key feeder program for the law-and-economics, regulation-skeptical right. That second credential, the JD from Yale Law plus the Olin training, is the chord that he's been playing ever since. He's a Supreme Court Bar member, licensed to practice medicine in Ohio, Florida, and Wisconsin (some sources also list New York), and licensed in law in Ohio and DC.

Clinically, the pattern is: BloodCenter of Wisconsin (molecular oncology director) → Cleveland Clinic (medical director of molecular pathology, oncology and germline) → OmniSeq (Chief Medical Officer of the Roswell Park spinout) → LabCorp (post-acquisition integration), with a side practice as Roger D. Klein MD JD Consulting and Klein & Klein Co., L.P.A. He has never run a federal agency, never had P&L responsibility for a workforce on the order of 300, and never managed an extramural grants portfolio. He has, however, sat at the AMP/CAP/ASCO/CLSI/AMA tables that touch federal policy — exactly the spot from which one criticizes federal agencies from the outside.

The AMP/CAP/AMA Resume — and Why It Matters

The single most consequential thing on Klein's pre-AHRQ resume is AMP v. Myriad Genetics. He was the AMP's expert and key public spokesperson in the 2013 case that invalidated patents on BRCA1 and BRCA2 — a genuinely landmark unanimous Supreme Court decision. That fact gives him a kind of permanent professional capital with the molecular pathology community: he was on the side of the angels, against gene patents, and against a corporate monopoly on diagnostic testing. This matters because it's the thing that lets him show up at AMP meetings and Executive War College and be taken seriously as a "leading figure in the field," even when his policy commitments have drifted far from the median AMP member.

At AMP itself he chaired the Professional Relations Committee 2011–2017 — i.e., the policy/advocacy/payment committee — sat on the AMP Board, chaired the Solid Tumors Subdivision, and in 2018 received AMP's Jeffrey A. Kant Leadership Award for "exceptional leadership." During his PRC tenure he was AMP's loudest public voice against FDA's 2014 proposed framework for laboratory-developed test oversight, calling FDA's "20 most problematic LDTs" report "a hodgepodge of outlier assays" and arguing the framework was "financially and administratively infeasible." That fight — physician-pathologist autonomy versus FDA premarket review — is a thread that runs through everything he has written since.

Beyond AMP, he held committee roles at CAP (FCAP designation), ASCO, CLSI, and the AMA, and — this is the part that should interest you most given his current chair of USPSTF appointments — he co-chaired CDC's Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. EGAPP was, in effect, the CDC's own little USPSTF for genomic and molecular tests, grading the evidence for clinical utility. So Klein has actually sat on a federal evidence-grading panel and knows from the inside exactly how "insufficient evidence" rulings get made and how they get used and abused. That experience cuts both ways: he understands the mechanics, and he distrusts them.

The Federalist Society Pipeline

The piece your AHRQ-watcher friends keep underplaying is the Regulatory Transparency Project track. Klein has been on the RTP FDA & Health Working Group for the better part of a decade, often appearing alongside David Hyman, Shoshana Weissmann (R Street), and others — the standard center-right deregulatory team. He is also a Faculty Fellow at the Center for Law, Science & Innovation at ASU's Sandra Day O'Connor Law School (a respectable center, but one that has trended libertarian on biotech), and on the Board of Advisors of the Liberty & Law Center at Antonin Scalia Law School at George Mason. Add a Policy Advisor slot at the Heartland Institute, and you have a recognizable map of the conservative health-policy infrastructure that doesn't run through AEI or Heritage but through the legal-conservative wing.

What he actually says in that environment is consistent. The themes:

• FDA shouldn't regulate LDTs as devices; the Clinical Laboratory Improvement Amendments framework is adequate.
• The administrative state is captured and slow; Chevron and Loper Bright were corrective.
• Gene patenting should remain narrow (his one consistently center-left position, via Myriad).
• Drug pricing controls (IRA negotiation) are misguided.
• COVID policy was an overreach by FDA and CDC; "overregulation" cost lives — this was the City Journal / NY Post / Manhattan Institute drumbeat in March–November 2020, including the influential "Confronting Covid" piece arguing Trump's response was "far better than critics acknowledge."

The COVID pieces in particular put him on the right-leaning podcast circuit that Quinn is alluding to: Larry O'Connor's Washington Examiner show; Breitbart News Saturday with Matt Boyle on SiriusXM; Steve Gruber; Sam Sorbo; Bill Spadea; the Heartland Institute's AnneMarie Schieber Health Care Podcast; the Federalist Society Fourth Branch and Deep Dive podcasts. Not Bannon's War Room — Klein's level is one tier up, the legal-conservative think-tank circuit rather than the populist talk-radio universe — but the through-line is clear. As recently as March 2025, he appeared on a Federalist Society panel on AHM v. FDA, the "chemical abortion drugs" case (i.e., mifepristone). That is a relevant data point: he has been publicly associated with a case challenging FDA scientific authority on a politically charged drug only months before being installed at AHRQ.

After his AHRQ appointment, the most striking media appearance is his interview on Dan Proft's "Chicago's Morning Answer" (560AM "The Answer"), with the LinkedIn caption "Federal Health Research Agency Refocuses on Patient Safety After Ideological Shift." That is not the language of a career civil servant. That is the language of someone who has decided that AHRQ as it existed was ideologically captured — and is going to say so on a conservative talk-radio program in Chicago — while running it. There is no obvious precedent for an AHRQ director publicly framing his predecessors' work as "ideological."

The Year of (Sic) Leadership

You said "sic" with irony. The record actually supports the irony.

Appointment. Klein was quietly added to the AHRQ Office of the Director page in July 2025, without a formal HHS announcement. The Connecticut Hospital Association reported HHS "quietly installed" him. This is unusual — most AHRQ directors get a press release.

The agency he inherited. AHRQ went into 2025 with ~916 employees and ~$484M in total appropriation, of which roughly $228M was the discretionary "core" appropriation and ~$11M was specifically tagged for USPSTF support. The March–April 2025 reduction in force under the broader HHS reorganization cut roughly 40 percent of the workforce, eliminated the office that processes grants entirely, hollowed out the dissemination and communications functions, and proposed to fold AHRQ into a new "Office of Strategy" merged with ASPE. Congress rejected the merger and gave AHRQ $345M for FY 2026 — a 6.4 percent cut, not the proposed elimination. Klein arrived after the layoffs were largely done, but on top of an agency that had been gutted.

What he has actually done. The Roll Call investigation by Jessie Hellmann (April 7, 2026) is the most damning. It establishes the following on the record, with named sources and HHS spokesman responses:

• AHRQ has spent none of the $345 million appropriated for FY 2026.
• The agency returned $80 million of its FY 2025 funding to the Treasury unspent — money Congress had appropriated and that AHRQ failed to obligate.
• No new research grants have been funded in almost a year.
• All grant-processing staff have left. ~90 employees remain of the original ~300 in the relevant program areas.
• Researchers with active multi-year awards have been left in limbo; phones aren't answered, emails aren't returned. Northwestern's Ron Ackermann has five grants stuck. Leora Horwitz (NYU): "You literally cannot submit to the agency. It is not possible to request funds from the agency."
• Klein, per a named-anonymous former employee, has "frequently denigrated existing projects as 'worthless,'" insists on personally reviewing every public-facing communication, and most submissions go into a "black hole."
• Panels that are supposed to meet several times a year to score grant applications have not met in a year.
• AHRQ has cancelled funding notices for antibiotic resistance and hospital-acquired infection research — exactly the areas where AHRQ's marquee historical contribution (Peter Pronovost's central-line-infection checklist work) has paid for the agency many times over.
• GAO is investigating whether this constitutes an impoundment of funds in violation of the Impoundment Control Act.
• The Society of General Internal Medicine and North American Primary Care Research Group are suing HHS (filed August 21, 2025) for unlawful impoundment of AHRQ grantmaking. HHS's position is that the appropriations are "a lump-sum that could be used for any purpose in furtherance of AHRQ's mission" — i.e., that Congress's directives are essentially advisory.
• AHRQ had to borrow FDA employees to push out some already-approved funding.
• The HHS FY 2027 budget request proposes a one-third cut, justified by AHRQ being "wasteful or duplicative of research conducted at NIH" and having "pushed radical gender ideology onto children." (That language is a tell. AHRQ funds health services research; the "gender ideology" framing is downstream of the same impulse that produced the American Conservative "Time for Kennedy to Kill the USPSTF" piece you've cited before.)

The HHS spokesman's reply is the standard "anonymous sources don't reflect reality" non-denial. Klein is "focused on ensuring the agency's work is aligned with its core mission and delivers meaningful value." Note what is conspicuously absent from that statement: any defense of the volume of grants made, papers issued, or guidelines produced. The Senate appropriators noticed; the FY 2026 funding law for the first time included statutory language directing HHS to "support staffing levels necessary to fulfill [AHRQ's] statutory responsibilities." A shot across the bow, and from observers' accounts, ignored.

The USPSTF piece specifically. Your clip is the May 22, 2026 PMO story. Layer it onto the timeline:

• The USPSTF has not formally met since March 2025.
• The July 2025 meeting was cancelled with two days' notice.
• The November 2025 meeting was cancelled during the government shutdown.
• The March 2026 meeting was confirmed cancelled.
• The last new recommendation was June 2025 (intimate partner violence screening).
• As of mid-May 2026 the Task Force is at 8 of 16 seats. The eight-month nomination cycle ran through May 23 — so Klein and Kennedy are sitting on the pen at the moment your clipping was published.
• Vice chairs Esa Davis and John Wong were fired May 11, 2026, in letters from RFK Jr. delivered May 12 in a meeting with Klein and an HHS attorney. Wong told PMO it was the first time he had met Klein. Read that sentence twice. The AHRQ director — whose statutory job is to "convene" the Task Force — had not met the Task Force chair in roughly ten months of tenure.
• The legal authority Klein cites for the firings is Kennedy v. Braidwood (SCOTUS June 2025), which confirmed the HHS Secretary's power to appoint and remove USPSTF members and to delay or veto their A/B recommendations — which is to say, Klein is using brand-new authority that no prior administration has ever used this way.
• Michael Barry (former chair) and Alex Krist (former chair) have publicly written that the inbound replacements appear to be "specialists" rather than primary care clinicians, raising the risk of disciplinary capture — exactly what Klein himself, in his PMO statement, frames as a feature ("recruiting specialists with real-world experience" to close "gaps between the Task Force recommendations and evolving medical practice").

Note the specific examples Klein gives PMO of those "gaps": ancillary breast screening for dense breasts, lung cancer screening in former smokers, and new modalities for colon cancer screening. Those are not random. They are exactly the screening areas where private payers and patient-advocacy groups (and, in fairness, some serious clinicians) have argued USPSTF is behind. They are also areas where industry stakeholders — including LabCorp, where Klein worked — have direct commercial interest. The breast-density example in particular is the FDA's new mandatory reporting rule colliding with USPSTF's older B-grade-mammography-only stance. It is not a crazy critique. But coming from the AHRQ director, as a public framing of USPSTF deficiency, with a half-empty Task Force he is about to repopulate, it functions as a thesis statement about where the new members will be ideologically tuned.

The Pattern You Noticed About I-Statements

You mentioned that you've watched USPSTF produce evidence reviews on "seemingly arcane topics which lack evidence for a recommendation — to the surprise of no one." You're right, and it's actually worth quantifying. Of roughly 90 topic areas and ~300 recommendations since 1984, somewhere between a quarter and a third of any given year's output is an I-statement (insufficient evidence). Recent examples: skin cancer screening (reaffirmed I), MCI screening (I), hearing-loss screening (I), food-insecurity screening (I — published March 2025, the last full topic before the meeting drought).

The USPSTF itself has been candid about this — see their 2010s methods paper acknowledging that "insufficiency of evidence is a common occurrence" and proposing the four-domain framework (preventable burden, intervention harm, cost, current practice) to give clinicians something to chew on when the evidence isn't enough for an A/B/C/D. Your critique has teeth: the agency is statutorily required to review what's nominated, the nomination process surfaces topics where industry/advocacy pressure exists, and the evidence base is what it is. So you get a lot of expensive systematic reviews ending in "we can't tell you."

The question is whether the Klein/Kennedy reform is responsive to that problem or orthogonal to it. The PMO quote — "recommendation timelines which can span two or more years for new guidance and five or more years for updates are increasingly difficult to reconcile with the pace of advances in medicine and technology" — is at least gesturing at a real problem. But the actual instrument they have deployed (firing the chairs, leaving the panel half-empty, letting the meetings lapse, returning unspent funds to Treasury, and stocking the Evidence-Based Practice Centers pipeline with nothing because no one is awarding contracts) does not look like an attempt to speed the agency up. It looks like an attempt to break it and replace it.

Net Assessment

A few things to surprise you, possibly, or at least to sharpen the picture:

First, Klein is not a crank. He is the most credentialed person ever to lead AHRQ on the molecular/diagnostic side — Yale med, Yale law, Mayo, Cleveland Clinic, AMP v. Myriad expert, EGAPP co-chair. The trouble is that AHRQ is not a molecular diagnostics agency. It is a health services research and patient safety agency, and Klein has essentially no track record in either of AHRQ's two core competencies (delivery science and patient safety methodology). His own LinkedIn-posted framing of the agency — "Refocuses on Patient Safety After Ideological Shift" — pointedly does not claim he is restoring the health services research mission. Patient safety is the part of AHRQ that even Republican appropriators have historically defended; he is dropping his weight on the politically safest leg of the stool while the rest of the stool collapses.

Second, the EGAPP and AMP v. Myriad parts of his resume are actually arguments against the way he is running USPSTF. Both EGAPP and the Myriad litigation depended on rigorous, slow, evidence-based work by panels that took time and refused to overclaim. Klein, in 2026, is essentially impatient with the same institutional posture he benefited from professionally for two decades.

Third, the impoundment piece is the under-covered legal vulnerability. Returning $80M of FY25 funding to Treasury, sitting on all of FY26, and having grant-processing staff at zero is the kind of fact pattern GAO and the courts can engage with. The SGIM/NAPCRG lawsuit is the vehicle. If GAO finds an unlawful impoundment, the Klein tenure is the case in point.

Fourth, the right-wing podcast presence is real but it's the legal-conservative tier, not the populist tier. He is not Jay Bhattacharya–style (Great Barrington, free-floating dissident). He is Federalist Society / Heartland / Manhattan Institute / Liberty & Law Center. That tier matters because it provides intellectual cover and continuity — these are the people who will write the post-hoc legal-theory papers explaining why what Klein did was within his statutory authority under Kennedy v. Braidwood. The Federalist Society's RTP has already been workshopping exactly those arguments since at least 2017.

Fifth, and worth holding onto: the Wong quote in your clip — "It was the first time Wong had met with Klein during his tenure" — is the most damning sentence in the article. Whatever one thinks about USPSTF reform, the AHRQ director's statutory job under the Public Health Service Act is to convene the Task Force. Not meeting the chair for ten months is not a reform philosophy. It is non-administration.

The fair summary, I think, is this: a credentialed and intellectually serious lawyer-pathologist with a long deregulatory track record was placed atop an agency he never seems to have particularly respected, after that agency had been cut by 40 percent, with statutory authority newly expanded by SCOTUS, and with a Secretary who had already used that same playbook to reconstitute the ACIP. One year in, the agency has not spent its money, has not funded new research, has not convened the Task Force it is statutorily required to support, and is being sued over impoundment while its director gives interviews to Chicago talk radio about ideological shift. The "leadership" — sic — is, charitably, an experiment in how much of a regulatory institution you can dismantle while still claiming to be running it. The Roll Call headline ("Nobody Answers") is the most precise three-word description of the year that I've seen.

Where this lands politically depends on whether the SGIM lawsuit and the GAO impoundment finding force a course correction before the rebuilt USPSTF starts issuing its first 2026–27 recommendations. The PMO article is the inflection point: Klein has now publicly committed to a June seating and a summer meeting. If that doesn't happen, the credibility cost of the Klein tenure compounds. If it does happen, the more interesting question is who he seats — because that, more than anything he has said on a podcast, will tell you what the new USPSTF is for.

---

Key sources, for your file: Hellmann, Roll Call, April 7, 2026 ("Nobody answers"); Byrne, Precision Medicine Online, May 22, 2026; The Hill / AOL, May 20, 2026 (Klein's email citing Kennedy v. Braidwood); Healio interview with Michael Barry, April 11, 2025; Senate "Friends of AHRQ" letter, March 14, 2025; Klein AHRQ bio (ahrq.gov); Klein personal site (rogerdklein.com — media appearances and op-eds list); FedSoc bio and RTP podcast/event archive; AMP 2018 Kant Award announcement; AMP v. Myriad (Supreme Court 2013); Klein's own LinkedIn (Proft and FedInsider posts); your own Discoveries in Health Policy August 4, 2025 post; King and Beyer/Blumenthal/Raskin congressional letters; Becker's Hospital Review aggregator of the Roll Call piece (April 8, 2026).